Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial

Fabian Frontzek, Marita Ziepert, Maike Nickelsen, Bettina Altmann, Bertram Glaß, Mathias Haenel, Lorenz Truemper, Gerhard Held, Martin Bentz, Peter Borchmann, Martin Dreyling, Andreas Viardot, Frank Kroschinsky, Bernd Metzner, Annette M. Staiger, Heike Horn, German Ott, Andreas Rosenwald, Markus Loeffler, Georg Lenz, Norbert Schmitz